Eyepoint Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $10,524 | $9,477 | $11,684 | $14,028 |
Gross Profit | 9,788 | 8,076 | 10,925 | 13,030 |
EBITDA | -32,748 | -30,464 | -28,980 | -13,904 |
EBIT | -33,156 | -30,826 | -29,283 | -14,016 |
Net Income | -29,361 | -30,826 | -29,284 | -14,099 |
Net Change In Cash | 10,524 | 9,477 | 11,684 | 14,028 |
Free Cash Flow | -40,602 | -21,078 | -32,365 | -23,992 |
Cash | 79,830 | 90,769 | 271,013 | 281,263 |
Basic Shares | 54,449 | 53,206 | 52,913 | 42,168 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $46,018 | $41,404 | $36,939 | $34,437 |
Gross Profit | 41,386 | 33,078 | 28,762 | 28,613 |
EBITDA | -69,001 | -96,619 | -50,148 | -35,488 |
EBIT | -69,465 | -99,065 | -52,919 | -38,137 |
Net Income | -70,795 | -124,512 | -63,915 | -52,651 |
Net Change In Cash | 46,018 | 41,404 | 36,939 | 34,437 |
Cost of Revenue | -82,960 | 133,684 | 22,695 | |
Free Cash Flow | -1,608 | -67,155 | -50,253 | -14,797 |
Cash | 281,263 | 95,633 | 178,593 | 44,909 |
Basic Shares | 38,904 | 37,317 | 28,758 | 12,836 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.54 |
2024-06-30 | -$0.58 |
2024-03-31 | -$0.55 |
2023-12-31 | -$0.33 |
